Subscribe To

Price Alert Latest News Economic Calendar News

PRTA / Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript

Prothena Corporation plc (NASDAQ:PRTA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Medical Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Wagner Zago - Chief Scientific Officer Conference Call Participants Michael Yee - Jefferies Neena Bitritto-Garg - Citi Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Abrahams - RBC Capital Markets Jason Butler - JMP Securities Operator Good afternoon. My name is Audra and I will be your conference operator today. Read More

Demo Live Account See Partner Details

Content Topics

Prothena

Corporation

PRTA

2022

Earnings

Call

Transcript

prta

Stock

Posted: Feb 24 2023, 00:33

Author Name: Seeking Alpha

PRTA News

By Zacks Investment Research
November 3, 2023

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

By Zacks Investment Research
November 2, 2023

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

Prothena (PRTA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares

By Zacks Investment Research
October 17, 2023

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the

By Proactive Investors
October 16, 2023

Prothena shares buoyed by sale rumors

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data f

By Reuters
October 16, 2023

Prothena prepares for potential sale - Bloomberg News

Biotech firm Prothena Corp is preparing for a potential sale, Bloomberg News reported on Monday, citing people with knowledge of the matter.

By Seeking Alpha
September 21, 2023

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX

By Zacks Investment Research
September 7, 2023

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

By Zacks Investment Research
August 4, 2023

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-lin

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.